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Abstract
In 2014, the EFSA NDA Panel concluded that UV-treated baker’s yeast containing up to 3.5 Mio IU of
vitamin D/100 g, is safe under the proposed conditions of use for yeast-leavened breads, rolls and fine
bakery wares, and food supplements. Following a request from the European Commission, the EFSA
Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on an
application for an extension of the use of UV-treated baker’s yeast as a novel food (NF) pursuant to
Regulation (EU) 2015/2283. In this extension of use, the applicant proposed a broad range of food
categories to which the NF can be added. On the basis of the proposed uses and maximum use levels,
the Panel estimated the potential exposure to vitamin D from the NF and the potential combined
exposure to vitamin D including also exposure from the background diet and food supplements. The
Panel notes that the upper level (UL) for one age group, i.e. children aged 4–10 years, is exceeded by
4%, when summing up the highest P95 estimate for the background diet (including food supplements)
and the highest P95 estimate for vitamin D from the NF under the proposed uses and maximum use
levels. The Panel notes, however, the highly conservative approach for estimating the potential intake
of vitamin D from the NF, given that the applicant has proposed 34 FoodEx2 level 2 food categories.
Thus, the Panel considers that the UL for children aged between 4 and 10 years is highly unlikely to be
exceeded. The Panel concludes that the NF is safe under the proposed conditions of use.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
On 15 May 2020, the company Lallemand Bio-Ingredients Division submitted a request to the
European Commission (EC) in accordance with Article 10 of Regulation (EU) 2015/22831 to authorise
an extension of the use of UV-treated baker’s yeast (Saccharomyces cerevisiae) as a novel food (NF).
The application requests to extend the use of UV-treated baker’s yeast (Saccharomyces cerevisiae)
in a number of foods.
In accordance with Article 10(3) of Regulation (EU) 2015/2283, the European Commission asks the
European Food Safety Authority to provide a scientific opinion on UV-treated baker’s yeast as a NF.
1.2. Additional information
In 2014, EFSA published a favourable opinion on the safety of ‘UV-treated baker’s yeast’ (EFSA NDA
Panel, 2014). That application concerned baker’s yeast which, due to UV radiation at a wavelength of
254 nm, contained between 1.8 and 3.5 Mio IU of vitamin D/100 g (450–875 lg/g). Following this
opinion, the EC granted marketing authorisation of this NF for its use in food supplements at a use
level that provides a maximum of 5 lg vitamin D2 per day and for yeast-leavened breads, rolls and
fine bakery at a use level that would not exceed a maximum concentration of 5 lg vitamin D2 per 100
g of the products marketed to consumers (European Commission, 2014).
Following an assessment by the competent Authority of Denmark of an application by Lallemand in
December 2016 (Denmark, 2016; unpublished), the Commission Implementing Regulation (EU) 2018/
1018 changed the description/definition and specifications of the NF due to the introduction of two
additional steps of the production process which included (1) an optional heating step (75°C for 10–15
minutes) resulting in an inactivation of the yeast and (2) blending with regular baker’s yeast to reduce
the vitamin D2 concentration to a lower level, i.e. a minimum of 800,000 IU/100 g (200 lg/g)
compared to the minimum level of 1,800,000 IU/100 g (450 lg/g) in the yeast concentrate authorised
in 2014 (European Commission, 2018). The application and authorisation included also an extension of
use of the NF to prepacked fresh or dry yeast for home baking and a deletion of the maximum use
level of the NF in food supplements.
The Panel also notes that other UV-treated NFs, i.e. UV-treated bread (EFSA NDA Panel, 2015), UV-
treated milk (EFSA NDA Panel, 2016a) and powder produced from Agaricus bisporus mushroom
exposed to UV irradiation, have been previously assessed and authorised (EFSA NDA Panel et al.,
2020). Another Opinion on a UV-treated mushrooms (Agaricus bisporus) powder was adopted in
February 2021 (EFSA NDA Panel, 2021).
2. Data and methodologies
2.1. Data
The safety assessment of this NF is based on data supplied in the application and information
submitted by the applicant following an EFSA request for supplementary information.
Administrative and scientific requirements for NF applications referred to in Article 10 of Regulation
(EU) 2015/2283 are listed in the Commission Implementing Regulation (EU) 2017/24691.
A common and structured format on the presentation of NF applications is described in the EFSA
guidance on the preparation and presentation of an NF application (EFSA NDA Panel, 2016b). As
indicated in this guidance, it is the duty of the applicant to provide all of the available (proprietary,
confidential and published) scientific data (including both data in favour and not in favour), that are
pertinent to the safety of the NF.
2.2. Methodologies
The assessment follows the methodology set out in the EFSA guidance on NF applications (EFSA
NDA Panel, 2016b) and the principles described in the relevant existing guidance documents from the
EFSA Scientific Committee. The legal provisions for the assessment are laid down in Article 11 of
1 Commission Implementing Regulation (EU) 2017/2469 of 20 December 2017 laying down administrative and scientific
requirements for applications referred to in Article 10 of Regulation (EU) 2015/2283 of the European Parliament and of the
Council on novel foods. OJ L 351, 30.12.2017, pp. 64–71.
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Regulation (EU) 2015/2283 and in Article 7 of the Commission Implementing Regulation (EU) 2017/
2469.
This assessment concerns only the risks that might be associated with consumption of the NF
under the proposed conditions of use, and is not an assessment of the efficacy of the NF with regard
to any claimed benefit.
3. Assessment
3.1. Specifications
According to the Commission implementing regulation (EU) 2018/1018 (European Commission,
2018), the authorisation concerns [citation]: ‘Baker’s yeast (Saccharomyces cerevisiae) is treated with
ultraviolet light to induce the conversion of ergosterol to vitamin D2 (ergocalciferol). Vitamin
D2 content in the yeast concentrate varies between 800,000 and 3,500,000 IU vitamin D/100 g (200–
875 lg/g). The yeast may be inactivated. The yeast concentrate is blended with regular baker’s yeast
in order not to exceed the maximum level in the pre-packed fresh or dry yeast for home baking. Tan-
coloured, free-flowing granules, vitamin D2: chemical name (5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10
(19),22-tetraen-3-ol, synonym: Ergocalciferol; CAS No.: 50-14-6; molecular weight: 396,65 g/mol’.
In addition, the following microbiological criteria have been set by the authorisation: Coliforms (≤ 103
cfu/g), Escherichia coli (≤ 10/g), Salmonella (absence in 25 g).
3.2. Proposed uses and use levels and anticipated intake
The NF is already authorised for its use in yeast-leavened breads, rolls and fine bakery at a use
level that would not exceed a maximum concentration of 5 lg vitamin D2 per 100 g of the products
marketed to consumer (European Commission, 2018). In addition, it has been permitted as prepacked
fresh or dry yeast for home baking with maximum use levels of 45 lg/100 g and 200 lg/100 g for
fresh and dried yeast, respectively. It has also been authorised for use in food supplements without
designated maximum use levels.
3.2.1. Proposed uses and use levels
In this application, the applicant seeks a number of additional uses, given in Table 1. This table
includes also the currently authorised uses under the two FoodEx codes A004V (i.e. ‘bread and similar
products’) and A009T (i.e. ‘Fine bakery wares’). Regarding the authorised use of the NF for prepacked
fresh or dry yeast for home baking, the Panel considers that intake estimates for the NF from yeast-
leavened bread and similar products and fine bakery wares baked at home would be covered by
consumption data for such products irrespective of whether they were produced industrially or baked
at home.
Considering the range of the vitamin D2 content in the NF (i.e. 200–875 lg/g), the maximum use
level of the NF to be added into the foods will be determined by the vitamin D content of a batch and
by the proposed maximum use level for vitamin D2 from the NF when added to various foods as
presented in Table 1.
Upon a question raised by EFSA, the applicant responded that the NF will be inactivated by heat
treatment before it is added to the newly intended foods (see also Section 1.2).
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levels of vitamin D2,
as consumed
(lg/100 g food)
Composite dishes Dishes, incl. ready-to-eat meals (excluding
soups and salads)
A03VB 3
Fried or extruded cereal, seed or root-based
products
A0EZX 5




Amphibians, reptiles, snails, insects A02KP 10
Food products for
young population
Infant formula (IF) and follow-on formula (FoF) A03PY 1.2(1)
Other food for infants and children A03RL 0.81
Processed cereal-based food for infants and
young children
A03QX 0.81(2)
Ready-to-eat meal for infants and young
children
A03RC 0.81
Fruit and fruit products Processed fruit products A01ML 1.5
Grains and grain-based
products
Bread and similar products(3) A004V 5
Breakfast cereals A00CV 4
Cereals and cereal primary derivatives A000K 3
Fine bakery wares(3) A009T 5








Isolated proteins and other protein products A0EVD 10
Maltodextrins and similar A0DPT 10
Miscellaneous agents for food processing A048P 10
Milk and dairy products Cheese A02QE 2
Dairy dessert and similar A02PT 2
Fermented milk or cream A02MZ 1.5
Milk and dairy powders and concentrates A02PD 25(4)
Milk, whey and cream A04NN 0. 5





Food for particular diets A03RR 5
Meat and dairy imitates A03TD 2.5
Seasoning, sauces and
condiments
Condiments (including table-top formats) A04QN 5
Dessert sauces/toppings A046QF 10
Mixed and other not-listed condiments A045J 10
Savoury extracts and sauce ingredients A0EQE 10
Seasonings and extracts A04QJ 10
Vegetables and
vegetable products
Algae and prokaryotes organisms A00VA 10
Fungi, mosses and lichens A00TC 10
Processed or preserved vegetables and similar A00ZA 2
(1): Based on the minimum use level of 1.2 lg vitamin D/100 g ready for use corresponding to 2 lg/100 kcal ready for use for
IF set by Commission Delegated Regulation (EU) 2016/127 (European Commission, 2016)2
2 https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32016R0127&from=FR
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3.2.2. Anticipated intake of the NF
EFSA performed an assessment of the anticipated daily intake of vitamin D2 from the NF based on
the applicant’s proposed uses and maximum proposed use levels indicated in Table 1, using individual
data from the EFSA Comprehensive European Food Consumption Database (EFSA, 2011). The
estimated lowest and highest mean and 95th percentile daily intake of vitamin D2 from the NF among
the EU dietary surveys is presented in Tables 2 and 3, expressed as lg/kg body weight (bw) per day
and lg per day, respectively.
The estimated daily intake of the NF for each population group from each EU dietary survey is
available in the Excel files annexed to this scientific opinion (under supporting information).
(2): Based on the minimum use level of 0.81 lg vitamin D/100 g ready for use corresponding to 1 lg/100 kcal ready for use
formula set by Commission Directive 2006/125/EC (European Commission, 2006) for processed cereal-based foods for
infants and young children.
(3): The use of the NF in yeast-leavened breads and rolls and yeast-leavened fine bakery wares has already been authorised, at
the proposed maximum levels.
(4): The proposed maximum vitamin D2 level in milk and dairy powders is 25 lg/100 g of dried powder and 2.5 lg/100 g for
the reconstituted milk.
Table 2: Estimated intake of the vitamin D2 (lg/kg bw per day) from the NF based on its use as an
ingredient in the intended food categories at the maximum proposed use levels
Population group Age (years)
Mean intake(a)
(lg/kg bw per day)
P95 intake(b)
(lg/kg bw per day)
Lowest Highest Lowest Highest
Infants < 1 0.46 1.67 1.38 3.45
Young children(c) 1–< 3 0.75 1.42 1.11 1.69
Other children 3–< 10 0.50 1.07 0.74 1.85
Adolescents 10–< 18 0.21 0.49 0.35 0.79
Adults(d) ≥ 18 0.13 0.40 0.24 0.68
(a): Mean intakes are assessed for all EU dietary surveys available in the food comprehensive database on 25/03/2021. The
lowest and the highest mean intake observed among all available EU surveys are reported in these columns.
(b): 95th percentile (P95) intakes are assessed for all EU dietary surveys available in the food comprehensive database on
25/3/2021. The lowest and the highest P95 intake observed among all available EU surveys are reported in these columns
(P95 based on less than 60 individuals are not considered).
(c): Referred as ‘toddlers’ in the EFSA food consumption comprehensive database (EFSA, 2011).
(d): Includes elderly, very elderly, pregnant and lactating women
Table 3: Estimated intake of the vitamin D2 (lg/day) from the NF based on its use as an ingredient
in the intended food categories at the maximum proposed use levels
Population group Age (years)
Mean intake (lg/day) P95 intake (lg/day)
Lowest(a) Highest(a) Lowest(b) Highest(b)
Infants < 1 3.94 10.38 11.60 20.08
Young children(c) 1–< 3 8.69 19.45 13.07 18.98
Other children 3–< 10 9.20 23.28 13.52 36.93
Adolescents 10–< 18 11.07 20.35 17.77 38.31
Adults(d) ≥ 18 10.04 29.21 17.32 40.46
(a): Intakes are assessed for all EU dietary surveys available in the food comprehensive database on 25/03/2021. The lowest
and the highest averages observed among all EU surveys are reported in these columns.
(b): 95th percentile (P95) intakes are assessed for all EU dietary surveys available in the food comprehensive database on
25/03/2021. The lowest and the highest P95 observed among all available EU surveys are reported in these columns (P95
based on less than 60 individuals are not considered).
(c): Referred as ‘toddlers’ in the EFSA food consumption comprehensive database (EFSA, 2011).
(d): Includes elderly, very elderly, pregnant and lactating women.
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3.2.3. Combined vitamin D intake from the NF and other sources
The potential combined intake of vitamin D from the NF (vitamin D2) and other sources (vitamin
D2 or D3) is estimated in Table 4 by adding up the contribution to vitamin D intake from the NF as
estimated by EFSA (Table 3) and estimates for vitamin D intake from other food sources as previously
reported by the EFSA NDA Panel based on a literature review (EFSA NDA Panel, 2012).
For infants aged from 4 to 12 months, data on vitamin D intake from the background diet were
estimated by EFSA using composition data from the EFSA nutrient composition database and individual
consumption data from national surveys from six European countries (EFSA NDA Panel, 2018). In that
Opinion, the Panel noted that the P95 vitamin D intake from the diet of non-formula fed infants and
excluding intake from fortified foods, ranged between 0.7 and 2.8 lg/day. The latter value (i.e. 2.8 lg/
day) is considered as high vitamin D intake from the background diet of older infants in Table 4, which
covers infants who consume IF. It is a conservative approach because IF-fed infants are expected to
consume less vitamin D from the background diet (excluding IF) than non IF-fed infants.
The P95 exposure from the background diet alone (without food supplements) was not available for
all children age groups above one year of age in the EFSA opinion from 2012, and as a substitute, the
highest mean intakes across the covered surveys for each age category of children were used (Table 4).
The highest mean intakes were 5.6 lg/day in young children (1–< 3 years), 2.7 lg/day in older children
(3–< 10 years) and 4.0 lg/day in adolescents (10–< 17 years). The P95 intakes from the background diet
plus from food supplements were, however, available for children of an age between 1 and 10 years (up
to 15 lg/day) and adolescents (up to 8 lg/day) in the EFSA NDA Panel opinion from 2012 and were also
used in the calculations in Table 4. The Panel considers that vitamin D2 intake from this NF when used in
food supplements, would most likely come as substitute for other food supplements and therefore not
increase overall vitamin D2 intake. In this 2012 Opinion, the highest P95 dietary background intake
(without food supplements) across the covered surveys in adults was 16 lg vitamin D/day.
Table 4 provides an overview of the exposure to vitamin D from different sources separately and
combined, and the tolerable upper intake levels (ULs) established for young children, children,
adolescents and adults (EFSA NDA Panel, 2012, 2018).
Table 4: Total vitamin D intake (lg/day) resulting from combined exposure to vitamin D from the










D2 intake from the NF
taken (from Table 3)
Total
intake(f)
UL* (lg/day) EFSA NDA
Panel (2012, 2018)
Infants < 1 2.8(c) 20.08 22.9 25/35(g)
Young children 1–< 3 5.6(d) 18.98 24.6 50
15(e) 18.98 34.0
Other children 3–< 10 2.7(d) 36.93 39.6 50
15(e) 36.93 51.9
Adolescents(a) 10–< 18 4(d) 38.31 42.3 100
8(e) 38.31 46.3
Adults(b) ≥ 18 16(d) 40.46 56.5 100
*: UL: tolerable upper intake level; NF: novel food.
(a): Food supplement for all adolescents: Intakes are assessed separately for young [10–14 years] and old adolescents [14–18
years]; the highest intake among these two sub-populations is reported here.
(b): Intakes are estimated separately for adults [18–65 years], elderly [65–75 years] and very elderly [≥ 75 years]; the highest
intake estimate among these three subpopulations is reported here. The figure represents the highest P95 consumption
estimate from foods excluding food supplements (EFSA NDA Panel, 2012).
(c): Highest P95 vitamin D intake from the diet of non-formula fed infants (EFSA NDA Panel, 2018, 2020).
(d): Highest mean or median intake of vitamin D from foods excluding food supplements. Data collected from different surveys/
studies (EFSA NDA Panel, 2012).
(e): Estimate for combined vitamin D intake from foods and supplements; vitamin D intake from high consumers (P90 or P95
depending on surveys) in infants, children and adolescents (EFSA NDA Panel, 2012).
(f): Total intake is the estimate of vitamin D intake calculated as the sum of vitamin D intake from the background diet with or
without food supplements (EFSA NDA Panel (2012), plus estimated P95 from the NF ingredient when used in foods.
(g): Upper level for vitamin D for infants up to 6 months of age (i.e. 25 lg/day) and with an age between 7 and 12 months (i.e.
35 lg/day), respectively (EFSA NDA Panel, 2018).
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According to scenarios covered by Table 4, the combined high intake estimates for vitamin D from
the background diet and the NF, would exceed the UL of 50 lg/day for ‘other children’ (aged 3–< 10
years) by 4%, when adding up the highest P95 estimate from the background diet (which included
consumption of food supplements) and the highest P95 estimate for vitamin D from the NF. The
scenarios of Table 4 do not consider exposure to vitamin D from food supplements by infants and
adults. For adults, however, there is a margin of 43.54 lg/day to the UL of 100 lg/day. For infants up
to 6 and 12 months of age, the margin to the UL is smaller, i.e. 2.12 and 12.12 lg/day, respectively.
The combined exposure estimates for vitamin D for infants and young children with an age of up to
3 years presented in Table 4, consider that the IF, FoF and processed cereal-based foods for infants
and young children contained the maximum use level as proposed by the applicant in Table 1 (i.e. 1.2
lg vitamin D/100 g ready for use IF and FoF and 0.81 lg vitamin D/100 g for ready for use ‘processed
cereal-based food for infants and young children’, respectively). The Panel notes however that
according to the Commission Delegated Regulation (EU) 2019/828 (European Commission, 2019)
amending Commission Delegated Regulation (EU) 2016/127 (European Commission, 2016), the
maximum permitted contents of vitamin D in IF and FoF are higher than the maximum use levels
proposed by the applicant for these foods. The permitted maximum contents are 2.5 and 3 lg vitamin
D per 100 kcal ready for use IF and FoF, respectively, which correspond to 1.5 and 1.8 lg vitamin D
per 100 g ready for use formulae, respectively. For processed cereal-based foods for infants and young
children, the maximum permitted content of vitamin D is 3 lg/100 kcal ready to use food according to
the Commission Directive 2006/125/EC (European Commission, 2006) corresponding to 2.43 lg
vitamin D/100 g ready to use food. These foods would contribute significantly to intake in these
groups, and hence, there are scenarios where vitamin D intake will approach the maximum permitted
levels. These are summarised in Table 5. For the vitamin D intake coming from the background diet,
the scenarios in Table 5 consider the same exposure estimates as used for the scenario in Table 4.
Regarding the exposure to the NF itself, at an exposure of e.g. 50 lg of vitamin D2 from the NF,
5.7–25 mg of the UV-treated yeasts would be consumed.
3.2.4. Estimate of exposure to undesirable substances
In their assessment from 2014, the NDA Panel noted that ‘the results of high-performance liquid
chromatography (HPLC) show that, apart from the intended vitamin D2, tachysterol was the only
additional sterol detected via HPLC analysis. According to the applicant, the average amounts of
vitamin D and tachysterol in the vitamin D2 yeast concentrate are 750 lg/g and 140 lg/g,
respectively’. The ratio between these contents of tachysterol and vitamin D and, i.e. 1/5.4, would also
apply to anticipated intakes presented in Section 3.2.1. Considering the low exposure to the NF, the
Panel considers that tachysterol is not of concern.
Table 5: Total vitamin D intake (lg/day) resulting from exposure to vitamin D from the background
diet (same values as used in Table 4) and to vitamin D from the NF as an ingredient at the
maximum use levels as proposed by the applicant – except regarding IF and FoF and
processed cereal-based food for infants and young children (for which the higher, legal
















Infants < 1 2.8(a) 22.09 24.89 25/35
Young children 1–< 3 5.6(b) 24.61 30.21 50
15(c) 24.61 39.61
*: Instead of the maximum use levels proposed by the applicant for IF and FoF, and processed cereal based foods for infants
and young children, the maximum legally permitted use levels are used in this exposure scenario.
(a): Highest P95 vitamin D intake from the diet of non-formula fed infants (EFSA NDA Panel, 2018, 2020).
(b): Highest mean or median intake of vitamin D from foods excluding food supplements. Data collected from different surveys/
studies (EFSA NDA Panel, 2012).
(c): Combined vitamin D intake from foods and supplements; vitamin D intake from high consumers (90th or 95th percentile
depending on surveys) in infants, children and adolescents (EFSA NDA Panel, 2012).
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4. Discussion
The Panel notes that the UL for ‘other’ children (aged 3 to < 10 years) is exceeded by 4%, when
adding up the highest P95 vitamin D intake estimate from the background diet (including food
supplements) and the highest P95 vitamin D intake estimate from the NF under the proposed uses and
maximum use levels. However, the Panel notes the conservative approach taken for estimating the
potential intake of vitamin D from the NF, given that the applicant has proposed 34 FoodEx2 level 2 food
categories. The intake estimates assume that whenever an individual consumes foods from these 34 food
categories, each consumed food from this list contains the NF at the maximum use levels proposed by the
applicant. Thus, the Panel considers that the UL for children aged between 3 and < 10 years is highly
unlikely to be exceeded at the uses and maximum use levels proposed by the applicant.
The exposure scenario for ‘young’ children (aged 1 to < 3 years), which include also exposure from
food supplements, suggest that the ULs for vitamin D would not be exceeded. This would also apply
for these children, and also for infants, if they would consume IF and FoF and processed cereal foods
for infants and young children containing the maximum permitted content of vitamin D set for these
foods.
Table 4 includes food consumption surveys for children between 1 and 18 years of age which also
covered combined consumption estimates for vitamin D from the diet including food supplements.
Under the assumption that the NF when used in food supplements would rather replace than add to
the intake of other vitamin D containing food supplements, the use of this NF in food supplements
would not result in an increase of vitamin D intake in children between 1 and 18 years of age.
For adults, the sum of the highest P95 estimate for the potential intake of vitamin D from the NF
and the highest mean intake from the diet without food supplements would result in a daily intake of
56.5 lg vitamin D, which would leave some margin to the UL for adults (i.e. 100 lg/day) regarding
food supplements.
The Panel notes limitations regarding the assessment of the potential combined exposure to
vitamin D from the NF and other sources. First, this exposure assessment does not consider potential
exposure from other authorised NFs with vitamin D such as UV-treated bread (EFSA NDA Panel, 2015),
UV-treated milk (EFSA NDA Panel, 2016a), UV-treated mushroom (EFSA NDA Panel et al., 2020). The
Panel also notes uncertainty regarding the calculated combined exposures to vitamin D of the general
population, given the fact that the range of foods fortified with vitamin D has increased over the years
as well as the marketing of high-dose vitamin D supplements. However, the Panel considers that the
applied approach for estimating the potential exposure to vitamin D from the NF is highly conservative
given the large number of food categories proposed by the applicant and used for the intake
estimates.
5. Conclusions
The Panel concludes that the NF is safe under the proposed conditions of use.
6. Steps taken by EFSA
1) On 29/01/2018 EFSA received a letter from the European Commission with the request for a
scientific opinion on the safety of Safety of extended uses of UV-treated baker’s yeast as a
Novel Food pursuant to Regulation (EU) 2015/2283 Ref. Ares(2018)470279.
2) On 07/07/2020, a valid application on the safety of Safety of extended uses of UV-treated
baker’s yeast as a Novel Food pursuant to Regulation (EU) 2015/2283, which was submitted
by name of the company, was made available to EFSA by the European Commission through
the Commission e-submission portal (NF 2020/1778) and the scientific evaluation procedure
was initiated.
3) On 19/03/2021, EFSA requested the applicant to provide additional information to accompany
the application and the scientific evaluation was suspended.
4) On 15/04/2021, additional information was provided by the applicant through the Commission
e-submission portal and the scientific evaluation was restarted.
5) During its meeting on 28/04/2021, the NDA Panel, having evaluated the data, adopted a
scientific opinion on the safety of Safety of extended uses of UV-treated baker’s yeast as a
Novel Food pursuant to Regulation (EU) 2015/2283 as a NF pursuant to Regulation (EU)
2015/2283.
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CAS Chemicals Abstracts Service
CFU colony forming units
FoF Follow-on formula
HPLC High Performance Liquid Chromatography
IF Infant formula
IU International Units
NDA Panel on Nutrition, Novel Foods and Food Allergens
NF Novel Food
P95 95th percentile
UL tolerable upper intake level
UV ultraviolet
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Annex A – Dietary exposure estimates to the Novel Food for each
population group from each EU dietary survey
Information provided in this Annex is shown in an Excel file (downloadable at https://efsa.onlinelib
rary.wiley.com/doi/10.2903/j.efsa.6602#support-information-section).
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